KRYS Krystal Biotech, Inc.
USHealthcareAs of 2026-07-10 16:00
Why KRYS matters now
Krystal Biotech, Inc. (KRYS) is a US stock in Healthcare. The latest InvestLog snapshot shows $365.81 with -1.46% on the session and $10.78B in market capitalization; recent performance reads 1-month +18.67% and YTD +41.18%.
The latest financial table shown here is Q1 2026, with revenue of $116.4M, net income of $55.9M, and EPS of $1.83. Investors can compare that operating picture with valuation signals such as P/E 36.96 and FCF yield 2.3%.
The latest indexable market news headline is "3 Soaring Stocks That May Have More Upside Ahead" from Fool - Investing News.
Additional event context on this page matters because analyst consensus is Buy with a median target of $327.00; recent insider activity includes Krishnan Krish S filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
36.96
PEG
0.28
P/B
7.98
P/S
24.59
EV/EBITDA
48.68
DCF Value
$546.59
FCF Yield
2.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
92.8%
Operating Margin
42.8%
Net Margin
53.9%
ROE
19.3%
ROA
16.1%
ROIC
13.9%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $116.4M | $55.9M | $1.83 |
| Q4 2025 | $107.1M | $51.4M | $1.70 |
| FY 2025 | $389.1M | $204.8M | $6.84 |
| Q3 2025 | $97.8M | $79.4M | $2.66 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$336.40
Target (Median)
$327.00
Target Range
$300.00 - $371.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.53
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.